The focus of this review is to compare and contrast two orphan disorders of late-onset hypoventilation. Specifically, rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) and congenital central hypoventilation syndrome (CCHS) are distinct in presentation, pathophysiology, and etiology.
INTRODUCTION
Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) is an orphan disorder, characterized by obesity and late-onset central hypoventilation, with key features reflected in the acronym. Because of the severe hypoventilation, the differential diagnosis of children with ROHHAD typically involves consideration of another rare disorder of respiratory and autonomic dysregulation, that is, congenital central hypoventilation syndrome (CCHS). While often described as overlapping syndromes, ROHHAD and CCHS are clinically and etiologically distinct. Despite the limited number of ROHHAD cases reported worldwide, there has been growing interest in understanding the etiology of this devastating syndrome. This review aims to provide an update on ROHHAD and compare and contrast ROHHAD and CCHS with attention to similarities and differences in presentation, pathophysiology, and etiology.
PRESENTATION AND EVALUATION
The earliest reported case consistent with the ROH-HAD phenotype was in 1965 [1] as late-onset central hypoventilation with hypothalamic dysfunction (LO-CHS/HD). It was not until 2000 that the first distinction between CCHS and LO-CHS/HD (later named ROHHAD) was presented by Katz et al. [2] describing one case in detail and a review of 10 previously reported cases in the literature. Katz and colleagues noted commonly reported signs and symptoms in LO-CHS/HD, which continue to be ROHHAD often presents with obesity Children with ROHHAD appear to have normal growth, development, and general health prior to onset of symptoms. The first signs of ROHHAD occur from 1.5 to 9 years of age and then progress over months to years. Rapid weight gain, such that the plotted weight on the growth curve crosses multiple percentiles by age and/or leaps beyond the standard curves above 97th percentile, is frequently the first sign. In 2007, Ize-Ludlow et al. [3] demonstrated that rapid-onset obesity was the earliest sign in the majority of patients and this was a major factor supporting the need to rename the syndrome.
When formalizing a patient's diagnosis of ROH-HAD, in addition to obesity, hypothalamic dysfunction should be investigated with evaluations for deficiency of growth hormone, Cushing's disease, water imbalance through aberrant vasopressin release (either partial vasopressin deficiency or transient syndrome of inappropriate antidiuretic hormone secretion), hypothyroidism, hyperprolactinemia, and hypogonadotropic hypogonadism [3, 4] . For individuals with CCHS, and in contrast to ROHHAD, endocrine abnormalities and obesity are not primary findings and would not be expected to occur in higher frequency than in the general population.
In ROHHAD, breathing abnormalities develop with variable timing either with or after onset of obesity and can consist of both obstructive sleep apnea and central hypoventilation. Notably, the hypoventilation becomes more apparent once upper airway obstruction is resolved. The development of hypoventilation can be subtle due to the patient's inability to appreciate developing hypercarbia and/ or hypoxemia and absence of clinical signs of respiratory distress, including absent sense of anxiety, with progressive inadequate ventilation [5] . Therefore, it is essential to obtain objective measures of ventilation with continuous pulse oximetry and end tidal/transcutaneous carbon dioxide monitoring during both sleep and wakefulness. Hypoventilation may present after 1 month of age, and these lateronset cases of CCHS may present some confusion with ROHHAD, but the absence of rapid weight gain and genetic testing can provide clear distinction.
CCHS presents with hypoventilation
In CCHS, hypoventilation often presents in the newborn period. The diagnostic evaluation confirms an absence of primary respiratory or cardiac disease, neuromuscular weakness, or central nervous system lesion. The late-onset cases of CCHS have been reported to occur with clinical presentations after 1 month of age and even into adulthood [6, 7] . Lateonset CCHS should be considered in infants that present with an event that is frightening to the caretaker, which includes apnea, cyanosis or pallor, altered muscle tone, or choking (also called apparent life-threatening event), or in young children with severe breath-holding spells [8] . For older children and adults, late-onset CCHS presentation can be more difficult to recognize and should be considered in the differential diagnosis with unexplained seizures or development of unanticipated hypercapnia (with or without intermittent hypoxemia) in the setting of physiologic challenge such as with surgery, sedation, or acute respiratory infection.
Autonomic nervous system dysregulation occurs in both ROHHAD and CCHS
Both CCHS and ROHHAD cases develop features of autonomic nervous system dysregulation (ANSD) [6] , again, with variable type and severity of symptoms. For ROHHAD, the most common findings of ANSD include ophthalmologic abnormalities (altered pupil response to light), altered thermoregulation (hyperthermia or hypothermia), gastrointestinal dysmotility (constipation or chronic diarrhea), and altered pain perception [3] . For ANSD in CCHS, Weese-Mayer et al. [9] comprehensively described the spectrum of ANSD in cases of CCHS, and the most common findings included decreased heart rate variability, altered gastrointestinal dysmotility (constipation, dysphagia), altered perception of pain, and KEY POINTS ROHHAD can be diagnosed in children older than 18 months, based on development of both rapid weight gain and central hypoventilation with additional associated features of hypothalamic dysfunction.
CCHS is diagnosed by the presence of hypoventilation in the absence of brainstem lesion, neuromuscular weakness, or a primary respiratory or cardiac disease and is characterized by PHOX2B gene mutation.
Repeated evaluations are necessary in children with either ROHHAD or CCHS because of the evolving clinical course and potential for devastating outcome of inadequate support for hypoventilation.
Management of children affected by ROHHAD is based on careful monitoring and therapeutic interventions that are supportive and symptom targeted, often requiring coordinated multisubspecialty care.
abnormalities of thermoregulation and diaphoresis. The ANSD in CCHS may be more prominent in those with a greater genetic burden [6] .
Tumors of neural crest origin have been described in both ROHHAD and CCHS. In ROHHAD, ganglioneuromas and ganglioneuroblastomas have been found in 33-40% of cases [6, 4, 10] , while, in CCHS, neuroblastomas, ganglioneuromas, and ganglioneuroblastomas have been reported in about 5% of all CCHS cases [11] , but are far more common in a subset of CCHS cases with certain paired-like homeobox 2B (PHOX2B) (vide infra) mutations [6, 11] . Of note, Hirschsprung disease can also be found in individuals with CCHS (referred to as Haddad syndrome), whereas Hirschsprung disease has not been reported in ROHHAD cases to date.
Adult cases have not been described in ROHHAD, but have with CCHS Case series regarding ROHHAD have focused on age at presentation and initial course. The latest age for first signs/presentation of ROHHAD is 9 years [12] . The high prevalence of cardiorespiratory arrest (50-60%) [3, 4] and subsequent mortality in a subset of those cases limits the information available regarding life expectancy and long-term outcomes. To the authors' knowledge, there are no reports describing ROHHAD cases beyond 18 years of age. On the other hand, cases of CCHS have been described in adults, both with presentation/diagnosis made in adulthood and those with early diagnosis who are now thriving as they advance into adulthood [6, 7] . Many of the adults diagnosed with CCHS have milder and rare mutations or have a genetic mosaicism. They may go unrecognized until they are stressed or have a child born with obvious symptomatic disease. Diagnostic and therapeutic recommendations have not been established for these adults, and support from a tertiary center should be considered.
DIAGNOSIS
Both ROHHAD and CCHS are categorized under sleep-related hypoventilation disorders in the International Classification of Sleep Disorders, third edition, as late-onset central hypoventilation with hypothalamic dysfunction and congenital central alveolar hypoventilation syndrome, respectively [13] .
ROHHAD is a clinical diagnosis
Diagnosis of ROHHAD is based on clinical criteria that must include rapid weight gain and hypoventilation occurring after 1.5 years of age. Additionally, there should be evidence of hypothalamic dysfunction (at least one of the following: rapidonset obesity, hyperprolactinemia, central 
Diagnosis of CCHS requires both clinical and genetic evaluation
The diagnosis of CCHS requires presence of both hypoventilation in the absence of primary neuromuscular, lung, cardiac disease, or brainstem lesion and abnormal genetic testing for PHOX2B [6] . Of large CCHS cohorts, PHOX2B mutations have been reported in 90-100% of cases and the presence is now considered requisite for diagnosis [6] . The third exon of the PHOX2B gene includes two polyalanine repeat regions ( Fig. 1) . Normally, the larger polyalanine repeat region has 20 alanines, with normal genotype noted as '20/20'. The majority of PHOX2B mutations found in CCHS cases are heterozygous polyalanine repeat expansion mutations (PARMs) that result in genotypes 20/24-20/33 (indicating 24-33 alanine repeats on the affected allele) [6] . Among PARMs, the most common genotypes are 20/25, 20/26, and 20/27 [6] . The remaining PHOX2B mutations found in CCHS include frameshift, nonsense, and missense mutations that typically disrupt the polyalanine repeat sequence (Fig. 2) and also result in functional disruption in the PHOX2B protein. These types of mutations are referred to as nonpolyalanine repeat expansion mutations (NPARMs). Rarely, heterozygous whole exon deletions of the PHOX2B gene are found [14] . Since the relatively recent discovery of PHOX2B mutations in 2003 as causative for CCHS, the understanding and significance of the genotypephenotype relationship has grown.
PATHOPHYSIOLOGY
At this time, the etiology of ROHHAD is elusive and interest has focused on possible genetic abnormalities, potential epigenetic changes, or an autoimmune process. Thus far, investigations of the ROHHAD candidate gene have not been fruitful, epigenetic investigations absent, and nonspecific evidence of an autoimmune phenomenon found. Genetic investigation has been pursued based on the overlapping features of ROHHAD and CCHS with attention to neuronal and autonomic nervous system development. In 2007, Ize-Ludlow et al. [3] were the first to clearly demonstrate that PHOX2B mutations are not present in ROHHAD cases, which was also confirmed by De Pontual et al. [10] . Although commercial testing for PHOX2B mutations is available, this testing should be pursued only if CCHS is suspected. Other genetic investigations in ROHHAD cohorts have related to hypothalamicspecific expression or development, including HTR1A (serotonin pathway), OTP, PACAP, ASCL1 (previously HASH-1), and NECDIN. [10, 15] . In looking at central nervous system development, genetic abnormalities were also not found in coding regions for neurotrophic tyrosine kinase receptor type 2 and brain-derived neurotrophic factor [3] . With report of monozygotic twins discordant for the ROHHAD phenotype [16] , genetic etiology appears to be less promising. Further, De Pontual et al. [10] are the only investigators thus far to report on genetic analysis of human leukocyte antigen and found alleles of the DQ subregion (HLA-DQ) in five of nine ROHHAD cases. Because children affected by ROHHAD appear to be healthy in infancy and early childhood, etiologies that would explain later presentation or explain neoplastic involvement have been proposed, such as epigenetic changes or a paraneoplastic response. Several diseases or disease processes have been shown to be associated with epigenetic abnormality, most commonly drawing comparison to Prader-Willi syndrome [17] . In contrast to Prader-Willi syndrome, individuals with ROHHAD do not have gradual onset of obesity or global developmental delay.
The concept of a paraneoplastic or autoimmune process was introduced in 1995 [18] . Because identification of neural crest tumors such as ganglioneuroma or ganglioneuroblastoma is found in only 33-39% of cases [3, 10] and disease progression is not clearly altered by removal of the tumor or with immunomodulatory or immunosuppressive therapy [16,19,20 & ], this avenue of treatment should also be undertaken with prudence. Recently, Sartori et al. [20 & ] demonstrated presence of oligoclonal bands in the cerebrospinal fluid (CSF) of two children with ROHHAD, providing stronger but nonspecific evidence of possible aberrant immune process.
CSF studies in ROHHAD cases have been recently reported that include low 5-hydroxyindoleacetic acid [21] , hypocretin-1 deficiency in a child with narcoleptic and cataplectic features [22] , elevated CSF cytometry for B-cell levels [16] , and, as stated earlier, presence of oligoclonal bands that were reported in two children with ROHHAD [20 & ]. With this, it may be worthwhile to give greater consideration to search for biomarkers that would facilitate diagnosis and monitor disease process. Ideally, any biomarker should provide reliable measures through a minimally invasive process. The advantage of CSF is that it potentially provides greater reliability in regards to a central nervous system process but poses challenges in obtaining repeated samples.
Considering these findings, it may be that etiology is more complex and may involve, for example, both an underlying predisposition (genetic) along with an instigating event (paraneoplastic). Although abnormalities to the orexin (also called hypocretin) system are proposed in the context of narcolepsy, for which the primary defect lies in wake-sleep state dysregulation; this does not adequately explain the features found in ROHHAD. More likely, the orexinergic projections to the medullary area and spinal cord involving upper airway dilator muscles, central chemoreception, diaphragmatic output, and autonomic projections [23] may contribute to the primary symptoms found in ROHHAD.
Paired-like homeobox 2B mutations define CCHS
Investigation of PHOX2B gene mutations in context of CCHS has remarkably grown over the past decade with clear, but not absolute, relationship of the type of mutation with the clinical phenotype. This progress has allowed improvements in clinical care through rapid/definitive diagnosis and anticipatory guidance. Found through basic science investigation, the PHOX2B gene plays an important role in embryologic development of the autonomic nervous system [24] . PHOX2B mutations cause alterations in localization of PHOX2B proteins to the cytoplasm instead of the nucleus of the cell that affect DNA binding due to aggregate formation (interfering with normal PHOX2B protein action) [11, 25] . The majority of findings regarding genotype-phenotype relationship in CCHS are found with the most common PHOX2B mutations, which are heterozygous polyalanine repeat expansions to 25, 26, and 27 repeats (also reported as +5, +6, and +7), which correspond to genotypes 20/25, 20/26, and 20/27. In brief, longer PARMs and NPARMs are associated with a more severe phenotype in regards to respiratory control deficit surmised from need for wakeful respiratory support [26] [27] [28] , prolonged sinus pause and associated cardiac pacemaker [29] , Hirschsprung disease [11, 28] , neural crest tumors [11, 28] , and pupillary response to light [30] . The CCHS cases that present and/or were diagnosed in adulthood generally have a milder phenotype and the PHOX2B 20/25 genotype.
The majority of cases occur due to de-novo mutation. Otherwise, the PHOX2B mutations in CCHS are inherited in an autosomal dominant pattern [6, 26] from a parent that has CCHS or a parent with somatic mosaicism [31, 32] . This is an important factor to consider when counseling families regarding risk for CCHS in any subsequent pregnancy. Of note, in order to detect low-level mosaicism [31, 32] , fragment analysis (DNA is segmented by restriction enzymes and then separated according to length by gel electrophoresis) should be the testing method of choice, while the more common sequencing testing will identify the majority of PARMs and NPARMs.
CONCLUSION
Although the etiology of ROHHAD continues to be elusive, the growing recognition and awareness of 1040-8703 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins www.co-pediatrics.com this disorder promises, at the least, to improve patient outcomes by facilitating early and conservative management. Furthermore, the growing awareness in itself suggests progress. The hope is that, with growing discussion and investigation into the overlap of ROHHAD with other disorders, greater insight will be gained into the underlying pathophysiology.
